Cargando…
Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Alzheimer’s disease (AD) is the most-common cause of neurodegenerative dementia, and it is characterized by abnormal amyloid and tau accumulation, which indicates neurodegeneration. AD has mostly been diagnosed clinically. However, ligand-specific positron emission tomography (PET) imaging, such as...
Autores principales: | Park, Sun Ah, Jang, Yu Jung, Kim, Min Kyoung, Lee, Sun Min, Moon, So Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262460/ https://www.ncbi.nlm.nih.gov/pubmed/35796265 http://dx.doi.org/10.3988/jcn.2022.18.4.401 |
Ejemplares similares
-
Diagnostic Blood Biomarkers in Alzheimer’s Disease
por: Park, Jung Eun, et al.
Publicado: (2022) -
Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
por: Wang, Min Jeong, et al.
Publicado: (2017) -
An Update on Endodontic Microsurgery of Mandibular Molars: A Focused Review
por: Jang, Sun Mi, et al.
Publicado: (2021) -
Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers
por: Lim, Tae Sung, et al.
Publicado: (2014) -
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
por: Colom-Cadena, Martí, et al.
Publicado: (2020)